20.500.12556/RUL-177179 Primerjava kakovosti življenja bolnic po prebolelem raku dojk: ženske iz programa DORA in bolnice iz raziskave OREH magistrsko delo Evaluation of quality of life of patients after breast cancer: women from the DORA program with patients who were included in the OREH research (study) master thesis Uvod: Kakovost življenja je večrazsežnostni pojem. Rak dojk in zdravljenje raka dojk ima lahko velik vpliv na kakovost življenja ženske. Namen: Državni presejalni programa za raka dojk DORA je namenjen odkrivanju raka dojk v zgodnjih fazah bolezni in zagotavlja boljšo kakovost življenja za žensko. Namen te raziskave je bil ugotoviti, ali obstaja razlika v kakovosti življenja med bolnicami, ki jim je bil rak diagnosticiran v okviru Državnega presejalnega programa DORA, in ostalimi bolnicami, ki so bile vključene v raziskavo OREH. Metode dela: Raziskava je bila izvedena kot retrospektivno neintervencijska študija s sekundarno analizo podatkov, predhodno pridobljenih z raziskavo OREH. Rezultate smo pridobili z analizo podatkov, pridobljenih s standardiziranim anketnim vprašalnikom EORTC QLQ C-30, ki so vnešeni v sistem RedCAP Onkološkega inštituta Ljubljana. Rezultati: Opravljena je bila statistična analiza vseh skupin (DORA_kontrolna, DORA_interventna, OREH_kontrolna, OREH_interventna). Kot statistično značilno smo dokazali le razliko v kakovosti življenja pred in po zdravljenju, merjeno z vprašanjem Q30 (p = 0,011). Pri večini skupin se zadovoljstvo pred in po zdravljenju največkrat (30 %) ohrani, po zdravljenju pa se poslabša kakovost življenja v OREH_kontrolni skupini. Bolnice v skupinah DORA so imele najpogosteje raka dojke stadija I (71 %), zgolj 4 % pa v višjih stadijih (stadij III in stadij IV), medtem ko so imele bolnice v skupinah OREH največkrat bolezen stadija II (45 %), vendar pa so imele pogosteje višje stadije (stadij III in stadij IV) v primerjavi s skupino DORA. Med kontrolnima skupinama (DORA_kontrolna, OREH_kontrolna) smo ugotovili boljšo kakovost življenja v skupini DORA_kontrolna pred zdravljenjem, merjeno z vprašanjem Q29 (p = 0,038) in vprašanjem Q30 (p = 0,047), po zdravljenju pa razlika več ni bila statistično značilna. Razprava in zaključek: Ugotovili smo, da največ bolnic (30 %) meni, da se jim kakovost življenja ohrani. Bolnice, napotene prek presejalnega programa DORA, imajo boljšo kakovost življenja po prebolelem raku dojk kot ostale bolnice z rakom dojk, vključene v raziskavo OREH. Vzrok za to je verjetno v tem, da je imelo vsaj 70 % žensk, napotenih prek programa DORA, nižji začetni stadij bolezni kot ostale bolnice iz programa OREH. Introduction: Quality of life is a multidimensional concept. Breast cancer and its treatment have a major impact on a woman's quality of life. Purpose: The national breast cancer screening program DORA is aimed at detecting breast cancer in the early stages of the disease, which also ensures a better quality of life for women. The purpose of this study was to determine whether there is a difference in quality of life between patients diagnosed with cancer within the National Breast Cancer Screening Program DORA and other patients included in the OREH study. Methods: The study was conducted as a retrospective non-interventional study with a secondary analysis of data previously obtained from the OREH study. The results were obtained by analyzing data obtained with the standardized EORTC QLQ C-30 questionnaire, which are entered into the RedCAP system of the Oncology Institute of Ljubljana. Results: A statistical analysis of all groups was performed (DORA_control, DORA_intervention, OREH_control, OREH_intervention). The only statistically significant difference was the difference in quality of life before and after treatment, measured by question Q30 (p=0.011). In most groups, satisfaction before and after treatment was most often maintained (30%), while after treatment, the quality of life of the OREH_control group worsened. Patients in the DORA groups most often had stage I breast cancer (71%) and only 4% in higher stages (stage III and stage IV), while patients in the OREH groups most often had stage II disease (45%), but they had higher stages more often (stage III and stage IV) compared to the DORA group. Between the control groups (DORA_control, OREH_control), we found better quality of life in the DORA_control group before treatment, measured by question Q29 (p=0.038) and question Q30 (p=0.047), but after treatment the difference was no longer statistically significant. Discussion and conclusion: We found that the largest proportion (30%) of patients believe that their quality of life is preserved. Patients referred through the DORA screening program have a better quality of life after breast cancer than other breast cancer patients included in the OREH study. The reason for this is probably that at least 70% of women referred through the DORA program had a lower initial stage of the disease than other patients from the OREH study. magistrska dela radiološka tehnologija mamografija rak dojk kakovost življenja OREH DORA master's theses radiologic technology mammography breast cancer quality of life OREH DORA true false false [S. Zafran Rojec] Slovenski jezik Angleški jezik Magistrsko delo/naloga 2025-12-17 11:24:22 2025-12-17 11:24:31 2025-12-28 04:09:44 0000-00-00 00:00:00 2025 0 Ljubljana 0 Ljubljana 43 str., [5] str. pril. 0000-00-00 NiDoloceno NiDoloceno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616-07 158161 261885699 57408.pdf 57408.pdf 1 11D84AABDED9DE574F58DEEAE7819ACB 98768389e94c8312348393f4fc5622b8801033c99713d42e1251ac537cfd75d3 228e1a55-db32-11f0-9328-0050569b8976 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=224078 Zdravstvena fakulteta 0 0 0